Literature DB >> 3981546

Dicesium N-succinimidyl 3-(undecahydro-closo-dodecaboranyldithio)propionate, a novel heterobifunctional boronating agent.

F Alam, A H Soloway, J E McGuire, R F Barth, W E Carey, D Adams.   

Abstract

The synthesis of a novel heterobifunctional agent, dicesium N-succinimidyl 3-(undecahydro-closo-dodecaboranyldithio)propionate, is described. This structure contains an active ester component known to react rapidly under very mild conditions with amino groups of proteins, resulting in covalent linkage. With use of this boronating agent, approximately 480 boron atoms have been incorporated per molecule of a polyclonal antibody directed against human thymocytes and 1300 boron atoms per molecule were incorporated into a monoclonal antibody, 17-1A, directed against human colorectal carcinoma cells. Binding of the boronated antibodies to the corresponding target cells was demonstrated by means of membrane immunofluorescence. There was some loss in reactivity, as determined by fluorescent end point titers, but specificity remained unchanged. The data suggest that boronated antibodies potentially could be used to selectively deliver boron-10 to tumor cells in order to achieve their destruction by neutron capture.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981546     DOI: 10.1021/jm00382a026

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  A targeting model of boron neutron-capture therapy to hepatoma cells in vivo with a boronated anti-(alpha-fetoprotein) monoclonal antibody.

Authors:  H Yanagië; Y Fujii; M Sekiguchi; H Nariuchi; T Kobayashi; K Kanda
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model.

Authors:  H Yanagië; T Tomita; H Kobayashi; Y Fujii; T Takahashi; K Hasumi; H Nariuchi; M Sekiguchi
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.